This article is more than 5 years old. Information may no longer be current.

Roswell Park Comprehensive Cancer Center researcher receives award to study kidney cancer vaccine

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

John Ebos, PhD, of the department of pharmacology and therapeutics at Roswell Park Comprehensive Cancer Center received a $792,000 multiyear research grant from American Cancer Society.

Patients with metastatic kidney cancer often stop treatment when their tumor becomes resistant to the therapies they are receiving.

Ebos is studying a vaccine designed to inhibit the tumor growth that often happens when treatment has stopped. If proven effective, this could provide additional time for patients and providers to identify new treatment options.

“The American Cancer Society research grant has changed the momentum of my work, providing financial stability for my lab and allowing me to find answers to questions we have been asking for more than 10 years,” Ebos said in a press release.

The cancer society provided 110 national research and training grants totaling more than $47.6 million. The grants, which will take effect July 1, will fund investigators at 72 institutions across the country.